The following complimentary webcasts are scheduled. Please register to participate.
Please be aware that webinars are hosted through GoToWebinar. If you are not already set up to view webinars through this service, please allow 5 minutes before the start to establish access.
Register for upcoming webinars here:
Date: October 23rd, 2014
Time: 16:00-16:40 BST (London time)
Molecular characterisation of circulating tumor cells (CTCs) and/or cell free tumor DNA (cfDNA) offers the opportunity for personalized targeted therapy and real-time monitoring of treatment efficacy.
The development of novel platforms to assess the presence of cfDNA is challenging due to the difficulty in obtaining a sustainable source of patient-relevant material. This webinar presents how the design and validation of our Multiplex Low Copy Number HDx™ Reference Standards and their performance in assays optimised for cfDNA detection.
We will discuss the clinical application, development and validation of Cell-free DNA assays.
Jonathan Frampton, PhD
In his role, Jonathan works closely with a broad range of European, North American and EMEA oncology-focussed Quality Assurance Schemes with the goal of driving the standardization and normalization of molecular assays across the globe.Jonathan holds a PhD from University of Sussex in Genomic DNA Damage and Stability and has extensive product development experience through previous roles including Cambridge-based antibody company Abcam.
Hadas Amit, PhD
Hadas is a senior scientist with a strong interest in the future of personalised medicine with focus on advances in cell free tumor DNA (cfDNA). Hadas is leading the research and development of cfDNA Reference Standards at Horizon Diagnostics.
Horizon Diagnostics, a business unit of Horizon Discovery Group plc is proud to support clinical laboratories with the provision of reference materials for research use; applications include the validation of equipment and consumables offline from patient testing. HDx™ Reference Standards are manufactured within a Quality Management System which complies with the requirements of ISO 9001:2008 and ISO 13485:2003.
Paragraph explaining benefits of Biocair×